Issues
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Articles
Antisense Oligodeoxyribonucleotide against the MLL-LTG19 Chimeric Transcript Inhibits Cell Growth and Induces Apoptosis in Cells of an Infantile Leukemia Cell Line Carrying the t(11;19) Chromosomal Translocation1
Frequent Somatic Mutations in Serine/Threonine Kinase 11/Peutz-Jeghers Syndrome Gene in Left-sided Colon Cancer1
Quantitative 1H Nuclear Magnetic Resonance Diffusion Spectroscopy of BT4C Rat Glioma during Thymidine Kinase-mediated Gene Therapy in Vivo: Identification of Apoptotic Response1
High Susceptibility of p53(+/-) Knockout Mice in N-Butyl-N-(4-hydroxybutyl)nitrosamine Urinary Bladder Carcinogenesis and Lack of Frequent Mutation in Residual Allele1
Telomerase Activity Exclusively in Cervical Carcinomas and a Subset of Cervical Intraepithelial Neoplasia Grade III Lesions: Strong Association with Elevated Messenger RNA Levels of Its Catalytic Subunit and High-Risk Human Papillomavirus DNA1
Synthetic Matrix Metalloproteinase Inhibitors and Tissue Inhibitor of Metalloproteinase (TIMP)-2, but not TIMP-1, Inhibit Shedding of Tumor Necrosis Factor-α Receptors in a Human Colon Adenocarcinoma (Colo 205) Cell Line
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.